ABOUT US SCIENCE PIPELINE PATIENTS & CAREGIVERS INVESTORS/MEDIA INSIDE SIGILON Rare Blood Disorders Rare blood disorders are a group of rare genetic disorders where the blood does not clot properly. Existing therapies for blood disorders place a high burden on patients and caregivers, requiring infusions as often as multiple times each week over a patient’s lifetime. At Sigilon, we recognize this burden and understand that living or caring for someone with a rare blood disorder is more than just an infusion. It’s a caregiver of a young child learning to recognize the signs of a bleed or an adult having trouble with venous access or having arthritis and limited joint mobility as a result of years of infusions and peaks and troughs of factor. Our Shielded Living Therapeutics™ platform has the potential to provide durable, consistent delivery of blood clotting factors for people with rare blood disorders. Clinical Trials Sigilon initiated a Phase 1/2 study in previously treated male patients with severe or moderately severe hemophilia A. The study is evaluating the safety, tolerability, and preliminary efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors across clinical centers in the United States (U.S.), United Kingdom (U.K.) and the European Union (E.U.). To learn more about the study, please visit the study listing on clinicaltrials.gov or on EudraCT. Note to the Hemophilia Patient Community Regarding our Clinical Hold Patient Resources North America Comprehensive Health and Education Services (CHES) Hemophilia Federation of America Hope For Hemophilia LA Kelly Communications National Hemophilia Foundation International European Haemophilia Consortium World Federation of Hemophilia BACK TO PATIENTS & CAREGIVER OVERVIEW ©2021 Sigilon Therapeutics, Inc. The marks SIGILON THERAPEUTICS, SIGILON, SHIELDED LIVING THERAPEUTICS, SLTX, AFIBROMER, AFIBROTEK, and our logos are trademarks of Sigilon Therapeutics, Inc. in the U.S. and other countries. All other marks are the property of their respective owners. Privacy Policy